An analysis of available biomarker data for targeting cyclin-dependent kinases 4 and 6 (CDK4/6) in breast cancer
Sign Up to like & getrecommendations! Published in 2019 at "Expert Review of Precision Medicine and Drug Development"
DOI: 10.1080/23808993.2019.1604136
Abstract: ABSTRACT Introduction: Inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6i) are a standard of care for advanced estrogen receptor (ER)–positive breast cancer in combination with hormonal therapy. Recent data from large trials comprising these agents… read more here.
Keywords: dependent kinases; kinases cdk4; cyclin dependent; breast cancer ... See more keywords